Acetaminophen; Oxycodone Hydrochloride Patent Expiration
Acetaminophen; Oxycodone Hydrochloride is Used for managing acute pain and treating patients with gastric retentive dosage form. It was first introduced by Mallinckrodt Inc
Acetaminophen; Oxycodone Hydrochloride Patents
Given below is the list of patents protecting Acetaminophen; Oxycodone Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xartemis Xr | US8658631 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia | May 16, 2032 | Mallinckrodt Inc |
| Xartemis Xr | US8741885 | Gastric retentive extended release pharmaceutical compositions | May 16, 2032 | Mallinckrodt Inc |
| Xartemis Xr | US8992975 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia | May 16, 2032 | Mallinckrodt Inc |
| Xartemis Xr | US9050335 | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia | May 16, 2032 | Mallinckrodt Inc |
| Xartemis Xr | US9468636 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia | May 16, 2032 | Mallinckrodt Inc |
| Xartemis Xr | US8597681 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | Dec 21, 2030 | Mallinckrodt Inc |
| Xartemis Xr | US8980319 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | Dec 21, 2030 | Mallinckrodt Inc |
| Xartemis Xr | US8377453 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic | Nov 19, 2029 | Mallinckrodt Inc |
| Xartemis Xr | US8372432 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic | Mar 11, 2029 | Mallinckrodt Inc |
| Xartemis Xr | US8394408 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic | Mar 11, 2029 | Mallinckrodt Inc |
| Xartemis Xr | US8668929 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic | Mar 11, 2029 | Mallinckrodt Inc |
| Xartemis Xr | US7976870 | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract | Jun 01, 2027 | Mallinckrodt Inc |
| Xartemis Xr | US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun 20, 2020
(Expired) | Mallinckrodt Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Acetaminophen; Oxycodone Hydrochloride's patents.
Latest Legal Activities on Acetaminophen; Oxycodone Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Acetaminophen; Oxycodone Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical
| 14 Aug, 2023 | US7976870 |
| Maintenance Fee Reminder Mailed Critical
| 27 Feb, 2023 | US7976870 |
| Expire Patent Critical
| 10 Jan, 2022 | US8597681(Litigated) |
| Maintenance Fee Reminder Mailed Critical
| 26 Jul, 2021 | US8597681(Litigated) |
| Expire Patent Critical
| 19 Apr, 2021 | US8394408 |
| Expire Patent Critical
| 29 Mar, 2021 | US8377453 |
| Expire Patent Critical
| 22 Mar, 2021 | US8372432 |
| Expire Patent Critical
| 23 Nov, 2020 | US9468636 |
| Maintenance Fee Reminder Mailed Critical
| 02 Nov, 2020 | US8394408 |
| Maintenance Fee Reminder Mailed Critical
| 12 Oct, 2020 | US8377453 |
Acetaminophen; Oxycodone Hydrochloride's Family Patents
